Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

New High-Sensitivity Breath Analyzer Enables Wide Range Multi-Biomarker Identification

By BiotechDaily International staff writers
Posted on 06 May 2013
Image: Microscope/Micrograph of MEMS micro-heating element with integrated CMOS electronic driver and temperature sensing circuits (Photo courtesy of Cambridge CMOS Sensors).
Image: Microscope/Micrograph of MEMS micro-heating element with integrated CMOS electronic driver and temperature sensing circuits (Photo courtesy of Cambridge CMOS Sensors).
Scientists and engineers have developed a gas-sensing technology that could enable multiple diseases and other conditions to be diagnosed and monitored using a single, highly sensitive breath analyzer.

Thousands of chemical compounds are exhaled with every breath. The infrared emitter developed by Cambridge CMOS Sensors (CCMOSS; Cambridge, UK) is a low-power, low-cost device capable of identifying more than 35 biomarkers present in exhaled human breath in concentrations as low as 1 part per million. “Noninvasive breath analysis is an area of great potential for diagnosing and monitoring a wide range of medical conditions,” said Professor Florin Udrea of the Dept. of Engineering and CCMOSS’ CEO and cofounder; “Testing is easy and painless, and can be repeated as often as needed.”

A number of breath analysis tests are currently in the R&D phase, most of which use mass spectrometry or lasers to analyze the breath for specific compounds. However, these tests can detect only a small range of compounds, so different devices are needed to detect different conditions. The CCMOSS technology differs in that it uses broadband infrared radiation to make the detection of a wide range of biomarkers possible in a single device. The miniature heaters, or microhotplates, can be heated from room temperature to 700 °C in a fraction of a second, a temperature high enough to emit infrared radiation and allow the sensing material to react with gas molecules.

Many gas molecules absorb infrared. The amount of radiation absorbed allows the gas to be identified and its concentration calculated - the basic principle behind, for example, the roadside breathalyzer test. CCMOSS’s technology, however, is far more sensitive - using broadband infrared, the gas sensor can detect wavelengths between 2 and 14 micronmeters, corresponding to a wide range of biomarkers. In order to detect different wavelengths, a filter is placed over the detector so that only infrared radiation of a particular wavelength can get through.

The company, a spinout from the University of Cambridge Department of Engineering, has been supported by seed funding from Cambridge Enterprise, the University’s commercialization arm. The CCMOSS technology is being developed for use in noninvasive medical analysis and other applications such as consumer electronics, industrial security, and automotive applications. It currently has a range of products available and is actively involved in R&D projects for next generation micro- and nanosensors.

Related Links:

University of Cambridge
Cambridge CMOS Sensors (CCMOSS)



view channel
Image: representation of a protein (blue), which contains three zinc fingers in complex with DNA (orange). The coordinating amino acid residues and zinc ions (green) are highlighted (Photo courtesy of Wikimedia Commons).

Molecular Sensors Generated by Synthetic Biology Technique Using Intein-Based Protein Splicing

Biotech researchers have used intein-based protein splicing to generate synthetic protein components that are able to detect specific DNA sequences and subsequently trigger a desired intracellular response... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.